Daiichi Sankyo
June 24, 2026
Theater 2
Type: Company Presentation
Focus Area:
Oncology
Daiichi Sankyo is a global healthcare company, committed to becoming a trusted healthcare innovator, transforming the lives of people through its strength in science and technology. The company discovers and develops new standards of care to address diverse medical needs to fulfill its purpose of contributing to the enrichment of quality of life around the world.
Company HQ City:
Basking Ridge
Company HQ State:
New Jersey
Company HQ Country:
Japan
Year Founded:
1899
Lead Product in Development:
Enhertu is the lead antibody drug conjugate (ADC) in the oncology portfolio of Daiichi Sankyo that was designed using the company’s propriety DXd ADC Technology. A comprehensive global clinical development program is underway evaluating the efficacy and safety of Enhertu as a monotherapy or in combination or sequentially with other cancer medicines across multiple HER2 targetable cancers.
CEO
Hiroyuki Okuzawa
Representative Director, President and CEO
Development Phase of Lead Product
Multiple Products in Market
Exchange
Tokyo Stock Exchange (TSE)
Ticker
TSE: 4568
When you expect your next catalyst update?
October 2026
What is your next catalyst (value inflection) update?
Daiichi Sankyo will have five practice-changing launches in 2026, including four new breast cancer indications for Enhertu and Datroway, as well as the company’s first-ever launch in small cell lung cancer with ifinatamab deruxtecan (I-DXd). The launch of Enhertu in first-line HER2 positive metastatic breast cancer (link) has been underway since the beginning of 2026, with two additional indications approved for Enhertu (link) in HER2 positive early stage breast cancer and one new indication for Datroway (link) in first-line metastatic triple negative breast cancer within one week in May 2026. The company’s next catalyst will be the pending U.S. approval of ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer by the PDUFA date of October 10, 2026, which potentially would be the third DXd antibody drug conjugate (ADC) to be approved for Daiichi Sankyo.
Primary Speaker
)
VP, Global Search & Evaluation – Early Stage, Global Business Development
Daiichi Sankyo
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}